Inverse relationship between brain noradrenaline level and dopamine loss in parkinson disease : A possible neuroprotective role for noradrenaline
Identifieur interne : 002920 ( Main/Exploration ); précédent : 002919; suivant : 002921Inverse relationship between brain noradrenaline level and dopamine loss in parkinson disease : A possible neuroprotective role for noradrenaline
Auteurs : JUNCHAO TONG [Canada] ; Oleh Hornykiewicz [Autriche] ; Stephen J. Kish [Canada]Source :
- Archives of neurology : (Chicago) [ 0003-9942 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: Experimental findings using animal models of Parkinson disease (PD) suggest that noradrenaline might protect dopamine neurons from damage. Objective: To assess whether human brain regions having high levels of noradrenaline are less susceptible to dopamine loss in PD. Design: Case-control study. Setting: Postmortem investigation. Participants: Autopsied brains of patients with PD and of healthy control subjects. Main Outcomes Measures: We compared the extent of dopamine loss in different regions relative to levels of noradrenaline found in healthy brain, with special attention devoted to the dopamine-rich nucleus accumbens, which has noradrenaline-rich and noradrenaline-poor subdivisions. Results: Among 20 brain areas, dopamine loss in PD was negatively correlated with healthy noradrenaline levels (r= 0.83), with regions rich in noradrenaline (eg, the noradrenaline-rich portion of the nucleus accumbens) spared from dopamine loss. However, within the striatum, noradrenaline levels in the caudate and putamen were similar, despite dopamine's being more markedly reduced in the putamen. Conclusions: Our postmortem data are consistent with animal findings suggesting that noradrenaline might affect dopamine neuron loss in PD and that a noradrenergic approach (although not aimed at the as yet unknown primary cause of PD) could be neuroprotective. This possibility should also be considered when noradrenergic therapy is provided for symptomatic purposes in PD.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000784
- to stream PascalFrancis, to step Curation: 000536
- to stream PascalFrancis, to step Checkpoint: 000718
- to stream Main, to step Merge: 002C16
- to stream Main, to step Curation: 002920
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inverse relationship between brain noradrenaline level and dopamine loss in parkinson disease : A possible neuroprotective role for noradrenaline</title><author><name sortKey="Junchao Tong" sort="Junchao Tong" uniqKey="Junchao Tong" last="Junchao Tong">JUNCHAO TONG</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Center for Brain Research, Medical University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>2 aut.</sZ></inist:fA14><country>Autriche</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0042041</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 07-0042041 INIST</idno><idno type="RBID">Pascal:07-0042041</idno><idno type="wicri:Area/PascalFrancis/Corpus">000784</idno><idno type="wicri:Area/PascalFrancis/Curation">000536</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000718</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000718</idno><idno type="wicri:doubleKey">0003-9942:2006:Junchao Tong:inverse:relationship:between</idno><idno type="wicri:Area/Main/Merge">002C16</idno><idno type="wicri:Area/Main/Curation">002920</idno><idno type="wicri:Area/Main/Exploration">002920</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inverse relationship between brain noradrenaline level and dopamine loss in parkinson disease : A possible neuroprotective role for noradrenaline</title><author><name sortKey="Junchao Tong" sort="Junchao Tong" uniqKey="Junchao Tong" last="Junchao Tong">JUNCHAO TONG</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Center for Brain Research, Medical University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>2 aut.</sZ></inist:fA14><country>Autriche</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Archives of neurology : (Chicago)</title><title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title><idno type="ISSN">0003-9942</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Archives of neurology : (Chicago)</title><title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title><idno type="ISSN">0003-9942</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Dopamine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Experimental findings using animal models of Parkinson disease (PD) suggest that noradrenaline might protect dopamine neurons from damage. Objective: To assess whether human brain regions having high levels of noradrenaline are less susceptible to dopamine loss in PD. Design: Case-control study. Setting: Postmortem investigation. Participants: Autopsied brains of patients with PD and of healthy control subjects. Main Outcomes Measures: We compared the extent of dopamine loss in different regions relative to levels of noradrenaline found in healthy brain, with special attention devoted to the dopamine-rich nucleus accumbens, which has noradrenaline-rich and noradrenaline-poor subdivisions. Results: Among 20 brain areas, dopamine loss in PD was negatively correlated with healthy noradrenaline levels (r= 0.83), with regions rich in noradrenaline (eg, the noradrenaline-rich portion of the nucleus accumbens) spared from dopamine loss. However, within the striatum, noradrenaline levels in the caudate and putamen were similar, despite dopamine's being more markedly reduced in the putamen. Conclusions: Our postmortem data are consistent with animal findings suggesting that noradrenaline might affect dopamine neuron loss in PD and that a noradrenergic approach (although not aimed at the as yet unknown primary cause of PD) could be neuroprotective. This possibility should also be considered when noradrenergic therapy is provided for symptomatic purposes in PD.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Canada</li></country><region><li>Vienne (Autriche)</li></region><settlement><li>Vienne (Autriche)</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Junchao Tong" sort="Junchao Tong" uniqKey="Junchao Tong" last="Junchao Tong">JUNCHAO TONG</name></noRegion><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002920 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002920 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:07-0042041
|texte= Inverse relationship between brain noradrenaline level and dopamine loss in parkinson disease : A possible neuroprotective role for noradrenaline
}}
| This area was generated with Dilib version V0.6.29. |  |